surmount-1 tirzepatide weight loss percent nejm 2022 For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The What to Expect on Tirzepatide:

GLP-1 medications like Wegovy and Zepbound have rapidly reshaped metabolic care, expanding from Type 2 diabetes treatment to widely used weight management tools when combined with diet and exercise

Krhenbhl, Eur

However, information related to pregnancy appears in Section 8.1 & 8.3 of the Prescribing Information for both Ozempic and Wegovy." A study is currently underway to evacuate the safety of Wegovy exposure during pregnancy, and is expected to be completed in August 2027

[1] Most do not affect the medication's efficacy

: : 72 : 6 (g) : 1.5 : 5 : -1 : 27% : 28% B12: 21% B2 (): 16% D: 6% : 5%

Further research is needed to elucidate these issues